N4 Pharma Company Description

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.

It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.

The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring.

N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

N4 Pharma Plc

Country	United Kingdom
Founded	1979
Industry	In Vitro and In Vivo Diagnostic Substances
Employees	4
CEO	Nigel Theobald

Contact Details

Address: 8 Bishopsgate London, EC2N 4BQ United Kingdom
Website	n4pharma.com

Stock Details

Ticker Symbol	0GO
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	GBP
SIC Code	2835

Key Executives

Name	Position
Nigel Theobald	Chief Executive Officer